An overview of the preclinical discovery and development of tezepelumab for the treatment of asthma

References

• Whetstone CE, Ranjbar M, Omer H, et al. The role of airway epithelium cell alarmins in asthma. Cells. 2022;11(7):1105. doi: 10.3390/cells11071105
   PubMed Web of Science ®Google Scholar
• Porsbjerg CM, Sverrild A, Lloyd CM, et al. Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics. Eur Respir J. 2020;56(5):2000260. doi: 10.1183/13993003.00260-2020
   PubMed Web of Science ®Google Scholar
• Mitchell PD, O’Byrne PM. Biologics and the lung: tSLP and other epithelial cell-derived cytokines in asthma. Pharmacol Ther. 2017;169:104–112. doi: 10.1016/j.pharmthera.2016.06.009
   PubMed Web of Science ®Google Scholar
• Verstraete K, Peelman F, Braun H, et al. Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma. Nat Commun. 2017;8(1):14937. doi: 10.1038/ncomms14937
   PubMedGoogle Scholar
• Ebina-Shibuya R, Leonard WJ. Role of thymic stromal lymphopoietin in allergy and beyond. Nat Rev Immunol. 2023;23(1):24–37. doi: 10.1038/s41577-022-00735-y
   PubMed Web of Science ®Google Scholar
• Varricchi G, Pecoraro A, Marone G, et al. Thymic stromal lymphopoietin isoforms, inflammatory disorders, and cancer. Front Immunol. 2018;9:1595. doi: 10.3389/fimmu.2018.01595
   PubMed Web of Science ®Google Scholar
• He R, Geha RS. Thymic stromal lymphopoietin. Ann N Y Acad Sci. 2010;1183(1):13–24. doi: 10.1111/j.1749-6632.2009.05128.x
   PubMedGoogle Scholar
• Matera MG, Rogliani P, Calzetta L, et al. TSLP inhibitors for asthma: current status and future prospects. Drugs. 2020;80(5):449–458. doi: 10.1007/s40265-020-01273-4
   PubMed Web of Science ®Google Scholar
• Yao W, Zhang Y, Jabeen R, et al. Interleukin-9 is required for allergic airway inflammation mediated by the cytokine TSLP. Immunity. 2013;38(2):360–372. doi: 10.1016/j.immuni.2013.01.007
   PubMed Web of Science ®Google Scholar
• Borowski A, Vetter T, Kuepper M, et al. Expression analysis and specific blockade of the receptor for human thymic stromal lymphopoietin (TSLP) by novel antibodies to the human TSLPRα receptor chain. Cytokine. 2013;61(2):546–555. doi: 10.1016/j.cyto.2012.10.025
   PubMed Web of Science ®Google Scholar
• Pattarini L, Trichot C, Bogiatzi S, et al. TSLP-activated dendritic cells induce human T follicular helper cell differentiation through OX40-ligand. J Exp Med. 2017;214(5):1529–1546. doi: 10.1084/jem.20150402
   PubMed Web of Science ®Google Scholar
• Kitajima M, Lee HC, Nakayama T, et al. TSLP enhances the function of helper type 2 cells. Eur J Immunol. 2011;41(7):1862–1871. doi: 10.1002/eji.201041195
   PubMed Web of Science ®Google Scholar
• Hui CC, Rusta-Sallehy S, Asher I, et al. The effects of thymic stromal lymphopoietin and IL-3 on human eosinophil-basophil lineage commitment: relevance to atopic sensitization. Immun Inflamm Dis. 2014;2(1):44–55. doi: 10.1002/iid3.20
   PubMedGoogle Scholar
• Klose CS, Artis D. Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis. Nat Immunol. 2016;17(7):765–774. doi: 10.1038/ni.3489
   PubMed Web of Science ®Google Scholar
• Liu S, Verma M, Michalec L, et al. Steroid resistance of airway type 2 innate lymphoid cells from patients with severe asthma: the role of thymic stromal lymphopoietin. J Allergy Clin Immunol. 2018;141(1):257–268. doi: 10.1016/j.jaci.2017.03.032
   PubMed Web of Science ®Google Scholar
• Mkorombindo T, Balkissoon R. Journal Club: biologics and potential for immune modulation in chronic obstructive lung disease. Chronic Obstr Pulm Dis. 2022;9(2):285–297. doi: 10.15326/jcopdf.2022.0318
   PubMed Web of Science ®Google Scholar
• Zhou B, Comeau MR, De Smedt T, et al. Thymic stromal lymphopoietin as a key initiator of allergic airway inflammation in mice. Nat Immunol. 2005;6(10):1047–1053. doi: 10.1038/ni1247
   PubMed Web of Science ®Google Scholar
• Chen ZG, Zhang TT, Li HT, et al. Neutralization of TSLP inhibits airway remodeling in a murine model of allergic asthma induced by chronic exposure to house dust mite. PLoS One. 2013;8(1):e51268. doi: 10.1371/journal.pone.0051268
   PubMed Web of Science ®Google Scholar
• Shi L, Leu SW, Xu F, et al. Local blockade of TSLP receptor alleviated allergic disease by regulating airway dendritic cells. Clin Immunol. 2008;129(2):202–210. doi: 10.1016/j.clim.2008.07.015
   PubMed Web of Science ®Google Scholar
• Chauhan A, Singh M, Agarwal A, et al. Correlation of TSLP, IL-33, and CD4 + CD25 + FOXP3 + T regulatory (Treg) in pediatric asthma. J Asthma. 2015;52(9):868–872. doi: 10.3109/02770903.2015.1026441
   PubMed Web of Science ®Google Scholar
• Ying S, O’Connor B, Ratoff J, et al. Expression and cellular provenance of thymic stromal lymphopoietin and chemokines in patients with severe asthma and chronic obstructive pulmonary disease. J Immunol. 2008;181(4):2790–2798. doi: 10.4049/jimmunol.181.4.2790
   PubMed Web of Science ®Google Scholar
• Wang W, Li Y, Lv Z, et al. Bronchial allergen challenge of patients with atopic asthma triggers an alarmin (IL-33, TSLP, and IL-25) response in the airways epithelium and submucosa. J Immunol. 2018;201(8):2221–2231. doi: 10.4049/jimmunol.1800709
   PubMed Web of Science ®Google Scholar
• Harada M, Hirota T, Jodo AI, et al. Thymic stromal lymphopoietin gene promoter polymorphisms are associated with susceptibility to bronchial asthma. Am J Respir Cell Mol Biol. 2011;44(6):787–793. doi: 10.1165/rcmb.2009-0418OC
   PubMed Web of Science ®Google Scholar
• Shikotra A, Choy DF, Ohri CM, et al. Increased expression of immunoreactive thymic stromal lymphopoietin in patients with severe asthma. J Allergy Clin Immunol. 2012;129(1):104–111. doi: 10.1016/j.jaci.2011.08.031
   PubMed Web of Science ®Google Scholar
• Salter BMA, Smith SG, Mukherjee M, et al. Human bronchial epithelial cell-derived factors from severe asthmatic subjects stimulate eosinophil differentiation. Am J Respir Cell Mol Biol. 2018;58(1):99–106. doi: 10.1165/rcmb.2016-0262OC
   PubMed Web of Science ®Google Scholar
• Park S, Park Y, Son SH, et al. Synthesis and biological evaluation of peptide-derived TSLP inhibitors. Bioorg Med Chem Lett. 2017;27(20):4710–4713. doi: 10.1016/j.bmcl.2017.09.010
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, RA P Jr, Taube C, et al. Development of an inhaled anti-TSLP therapy for asthma. Pulm Pharmacol Ther. 2023;78:102184. doi: 10.1016/j.pupt.2022.102184
   PubMed Web of Science ®Google Scholar
• FDA. Center for drug evaluation and research. Application number 761224Orig1s000. [Last accessed Apr 18, 2023]. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761224Orig1s000MultidisciplineR.pdf.
   Google Scholar
• GM G, PM O, LP B, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med. 2014;370(22):2102–2110. doi: 10.1056/NEJMoa1402895
   PubMed Web of Science ®Google Scholar
• Sverrild A, Hansen S, Hvidtfeldt M, et al. The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM). Eur Respir J. 2021;59(1):2101296. doi: 10.1183/13993003.01296-2021
   PubMed Web of Science ®Google Scholar
• Sverrild A, Cerps S, Nieto-Fontarigo J, et al. Effects of tezepelumab on host epithelial tolerance to virus in patients with uncontrolled asthma [abstract]. Eur Respir J. 2021;58(Suppl 65):OA1492.
   Google Scholar
• Diver S, Khalfaoui L, Emson C, et al. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299–1312.
   PubMed Web of Science ®Google Scholar
• Brightling CE, O’Byrne PM, Porsbjerg C, et al. Effect of tezepelumab on airway hyperresponsiveness by baseline blood eosinophil count in patients with severe, uncontrolled asthma in the phase 2 CASCADE study [abstract]. Am J Respir Crit Care Med. 2023;207:A4760.
   Google Scholar
• Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936–946. doi: 10.1056/NEJMoa1704064
   PubMed Web of Science ®Google Scholar
• Corren J, Chen S, Callan L, et al. The effect of tezepelumab on hospitalizations and emergency department visits in patients with severe asthma. Ann Allergy Asthma Immunol. 2020;125(2):211–214. doi: 10.1016/j.anai.2020.05.020
   PubMed Web of Science ®Google Scholar
• Corren J, Pham TH, Garcia Gil E, et al. Baseline type 2 biomarker levels and response to tezepelumab in severe asthma. Allergy. 2022;77(6):1786–1796. doi: 10.1111/all.15197
   PubMed Web of Science ®Google Scholar
• Emson C, Corren J, Sałapa K, et al. Efficacy of tezepelumab in patients with severe, uncontrolled asthma with and without nasal polyposis: a post hoc analysis of the phase 2b PATHWAY study. J Asthma Allergy. 2021;14:91–99. doi: 10.2147/JAA.S288260
   PubMed Web of Science ®Google Scholar
• Corren J, Ambrose CS, Sałapa K, et al. Efficacy of tezepelumab in patients with severe, uncontrolled asthma and perennial allergy. J Allergy Clin Immunol Pract. 2021;9(12):4334–4342. doi: 10.1016/j.jaip.2021.07.045
   PubMed Web of Science ®Google Scholar
• Pham TH, Chen C, Colice G, et al. Tezepelumab normalizes serum interleukin-5 and -13 levels in patients with severe, uncontrolled asthma. Ann Allergy Asthma Immunol. 2021;127(6):689–691. doi: 10.1016/j.anai.2021.08.008
   PubMed Web of Science ®Google Scholar
• Corren J, Garcia Gil E, Griffiths JM, et al. Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY. Ann Allergy Asthma Immunol. 2021;126(2):187–193. doi: 10.1016/j.anai.2020.10.008
   PubMed Web of Science ®Google Scholar
• Corren J, Larson D, Altman MC, et al. Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: a randomized controlled trial. J Allergy Clin Immunol. 2023;151(1):192–201. doi: 10.1016/j.jaci.2022.08.029
   PubMed Web of Science ®Google Scholar
• Parnes JR, Sullivan JT, Chen L, et al. Pharmacokinetics, safety, and tolerability of tezepelumab (AMG 157) in healthy and atopic dermatitis adult subjects. Clin Pharmacol Ther. 2019;106(2):441–449. doi: 10.1002/cpt.1401
   PubMed Web of Science ®Google Scholar
• Sakamoto K, Matsuki S, Irie S, et al. A phase 1, randomized, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous tezepelumab in healthy Japanese men. Clin Pharmacol Drug Dev. 2020;9(7):833–840. doi: 10.1002/cpdd.775
   PubMed Web of Science ®Google Scholar
• Zheng Y, Abuqayyas L, Megally A, et al. Tezepelumab pharmacokinetics, safety, and tolerability after administration via vial-and-syringe, accessorized prefilled syringe, or autoinjector: a randomized trial in healthy volunteers. Clin Ther. 2021;43(1):142–155. doi: 10.1016/j.clinthera.2020.11.014
   PubMed Web of Science ®Google Scholar
• Hoy SM. Tezepelumab: first approval. Drugs. 2022;82(4):461–468. doi: 10.1007/s40265-022-01679-2
   PubMed Web of Science ®Google Scholar
• Ly N, Zheng Y, Griffiths JM, et al. Pharmacokinetic and pharmacodynamic modeling of Tezepelumab to guide phase 3 dose selection for patients with severe asthma. J Clin Pharmacol. 2021;61(7):901–912. doi: 10.1002/jcph.1803
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800–1809. doi: 10.1056/NEJMoa2034975
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Menzies-Gow A, Brightling CE, et al. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study. Lancet Respir Med. 2022;10(7):650–660. doi: 10.1016/S2213-2600(21)00537-3
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Wechsler ME, Brightling CE, et al. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study. Lancet Respir Med. Online ahead of print 2023;11:425–438. doi: 10.1016/S2213-2600(22)00492-1
   PubMed Web of Science ®Google Scholar
• Shinkai M, Ebisawa M, Fukushima Y, et al. One-year safety and tolerability of tezepelumab in Japanese patients with severe uncontrolled asthma: results of the NOZOMI study. J Asthma. 2023;60(3):616–624. doi: 10.1080/02770903.2022.2082309
   PubMed Web of Science ®Google Scholar
• Alpizar S, Megally A, Chen C, et al. Functionality and performance of an accessorized pre-filled syringe and an autoinjector for at-home administration of tezepelumab in patients with severe, uncontrolled asthma. J Asthma Allergy. 2021;14:381–392. doi: 10.2147/JAA.S305114
   PubMed Web of Science ®Google Scholar
• Corren J, Menzies-Gow A, Chupp G, et al. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of PATHWAY and NAVIGATOR studies. Am J Respir Crit Care Med. 2023. 10.1164/rccm.202210-2005OC. Online ahead of print
   PubMedGoogle Scholar
• Corren J, Wechsler ME, Chupp G, et al. Efficacy and safety of tezepelumab in patients with uncontrolled disease while receiving maintenance therapy for moderate or severe asthma. J Allergy Clin Immunol Pract. 2023;11(3):943–945. doi: 10.1016/j.jaip.2022.10.042
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Ambrose CS, Cook W, et al. Efficacy of tezepelumab in patients grouped by pre-treatment percent predicted FEV1: a pooled analysis of the PATHWAY and NAVIGATOR studies [abstract]. Am J Respir Crit Care Med. 2023;207:A5996.
   Google Scholar
• Mathur S, Hill J, Ambrose C, et al. Tezepelumab efficacy by SNOT-22 score in patients with severe, uncontrolled asthma and comorbid nasal polyps in NAVIGATOR [abstract]. J Allergy Clin Immunol. 2023;151(2 Suppl):AB17. doi: 10.1016/j.jaci.2022.12.057
   Web of Science ®Google Scholar
• Carr W, Ambrose C, Hunter G, et al. Effect of tezepelumab on rescue medication use and night-time awakenings in patients with severe, uncontrolled asthma: results from the NAVIGATOR study [abstract]. J Allergy Clin Immunol. 2023;151(2 Suppl):AB14.
   Web of Science ®Google Scholar
• Castro M, Kraft M, Ambrose CS, et al. Tezepelumab reduces patient-reported cough and phlegm production in patients with severe, uncontrolled asthma: results from the phase 3 NAVIGATOR study [abstract]. Am J Respir Crit Care Med. 2023;207:A4752.
   Google Scholar
• Corren J, Ambrose CS, Griffiths JM, et al. Efficacy of tezepelumab in patients with evidence of severe allergic asthma: results from the phase 3 NAVIGATOR study. Clin Exp Allergy. 2023;53(4):417–428. doi: 10.1111/cea.14256
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Colice G, Ambrose CS, et al. Efficacy of tezepelumab in patients with severe, uncontrolled asthma by prior omalizumab use: a post hoc analysis of the phase 3 Navigator study [abstract]. Am J Respir Crit Care Med. 2023;207:A2764.
   Google Scholar
• FDANews. FDA awards AstraZeneca and Amgen’s tezepelumab breakthrough designation. Available at: https://www.fdanews.com/articles/188355-fda-awards-astrazeneca-and-amgens-tezepelumab-breakthrough-designation. Last accessed Nov 10, 2019.
   Google Scholar
• Amgen. Tezepelumab granted priority review by U.S. FDA. Available at: https://www.amgen.com/newsroom/press-releases/2021/07/tezepelumab-granted-priority-review-by-u-s–fda. Last accessed Apr 20, 2023.
   Google Scholar
• FDA. FDA approves maintenance treatment for severe asthma. Available at: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-maintenance-treatment-severe-asthma. Last accessed Apr 20, 2023.
   Google Scholar
• AstraZeneca. TEZSPIRE approved for self-administration in the US with a new pre-filled pen. Available at: https://www.astrazeneca-us.com/media/press-releases/2023/tezspire_approved_for_self_administration_in_the_us_with_a_new_pre_filled_pen.html. Last accessed Apr 20, 2023.
   Google Scholar
• European Medicines Agency. Tezspire. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/tezspire#authorisation-details-section. Last accessed Apr 20, 2023.
   Google Scholar
• AstraZeneca. Tezspire approved for self-administration in the EU in a new pre-filled pen. Available at: https://www.astrazeneca.com/media-centre/press-releases/2023/tezspire-approved-for-self-administration-in-the-eu-in-a-new-pre-filled-pen.html. Last accessed Apr 20, 2023.
   Google Scholar
• AstraZeneca. Tezspire approved in Japan for the treatment of severe asthma. Available at: https://www.astrazeneca.com/media-centre/press-releases/2022/tezspire-approved-in-japan-for-severe-asthma.html. Last accessed Apr 20, 2023.
   Google Scholar
• AstraZeneca. Tezspire™ (tezepelumab injection) now available in Canada for severe asthma. Available at: https://www.astrazeneca.ca/en/media/press-releases/2022/tezspire—tezepelumab-injection–now-available-in-canada-for-se.html. Last accessed Apr 20, 2023.
   Google Scholar
• Kurihara M, Kabata H, Irie M, et al. Current summary of clinical studies on anti-TSLP antibody, Tezepelumab, in asthma. Allergol Int. 2023;72(1):24–30. doi: 10.1016/j.alit.2022.11.006
   PubMed Web of Science ®Google Scholar
• Gershon AS, Jafarzadeh SR, Wilson KC, et al. Clinical knowledge from observational studies. Everything you wanted to know but were afraid to ask. Am J Respir Crit Care Med. 2018;198(7):859–867. doi: 10.1164/rccm.201801-0118PP
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Steenkamp J, Singh S, et al. Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison. J Med Econ. 2022;25(1):679–690. doi: 10.1080/13696998.2022.2074195
   PubMed Web of Science ®Google Scholar
• Nopsopon T, Lassiter G, Chen ML, et al. Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a Bayesian network meta-analysis. J Allergy Clin Immunol. 2023;151(3):747–755. doi: 10.1016/j.jaci.2022.11.021
   PubMed Web of Science ®Google Scholar
• Plaza V, Cañete C, Domingo C, et al. Efficacy and potential positioning of tezepelumab in the treatment of severe asthma. Open Respir Arch. 2023;5:100231. doi: 10.1016/j.opresp.2022.100231
   Google Scholar
• Couillard S, Pavord ID, Heaney LG, et al. Sub-stratification of type-2 high airway disease for therapeutic decision-making: a ‘bomb’ (blood eosinophils) meets ‘magnet’ (FeNO) framework. Respirology. 2022;27(8):573–577. doi: 10.1111/resp.14294
   PubMed Web of Science ®Google Scholar
• Shrimanker R, Keene O, Hynes G, et al. Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide, and their combination in severe asthma: a post hoc analysis. Am J Respir Crit Care Med. 2019;200(10):1308–1312. doi: 10.1164/rccm.201903-0599LE
   PubMed Web of Science ®Google Scholar
• Agusti A, PG G, VM M. Treatable traits in airway disease: from theory to practice. J Allergy Clin Immunol Pract. 2023;11(3):p. 713–723.
   Google Scholar
• Melhorn J, Howell I, ID P. Should we apply a treatable traits approach to asthma care? Ann Allergy Asthma Immunol. 2022;128(4):p. 390–397.
   Google Scholar
• Athari SS. Targeting cell signaling in allergic asthma. Signal Transduct Target Ther. 2019;4(1):45. doi: 10.1038/s41392-019-0079-0
   PubMed Web of Science ®Google Scholar